Multiantigenic subunitary vaccines against tuberculosis in clinical trials: Where do we stand and where do we need to go?

Carolina Guapillo, Rogelio Hernández-Pando, Mario Alberto Flores-Valdez

Journal: Human vaccines & immunotherapeutics 2017;12(5):1193-5

PMID: 27049797

Abstract

The idea of presenting this commentary is to bring attention to the current status of clinical tests from several multiantigen vaccine candidates based on proteins produced by means of genetic engineering and molecular biology approaches and to suggest how new emerging technologies (OMICs) and bioinformatics might benefit vaccine development for better control of tuberculosis.

Address: a Sección de Patología Experimental , Departamento de Patología, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán" , Mexico DF.; b Centro de Investigación y Asistencia en Tecnología y diseño del Estado de Jalisco, A.C., Biotecnología Médica y Farmacéutica, Col. Colinas de la Normal , Guadalajara , Jalisco , México.

DOI: 10.1080/21645515.2015.1136760

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/tuberculosis.html

Other Literature Sources:

https://scite.ai/reports/27049797

MeSH Terms: Antigens, Bacterial, BCG Vaccine, Clinical Trials as Topic, Computational Biology, Drug Design, Humans, Mycobacterium tuberculosis, Tuberculosis, Tuberculosis Vaccines, Vaccines, Subunit